Quadria Capital Closes Oversubscribed US$1 Billion Fund III to Advance Healthcare Transformation Across Asia
Existing investors increased commitment amount by an average of 80%
New capital raised from blue-chip global institutions, alongside a significant rise in Asian investor participation
Quadria Capital, Asia's premier healthcare-focused private equity firm, today announced the final close of its Fund III with US$1.07 billion in total commitments, significantly exceeding its original $800 million target.
The oversubscribed fundraise comprises over US$954 million in primary commitments and US$114 million in committed co-investment capital. An additional US$300 million co-investment capacity is anticipated over the course of the investment phase, bringing total committed capital to approximately US$1.3 billion upon full deployment.
This latest fundraise is around 60% larger than the firm's previous $600m fund raised in 2020, cementing Quadria's position as the largest dedicated healthcare private equity fund in South and Southeast Asia.
'Fund III's close, amid one of the most demanding fundraising climates in recent memory, is a powerful validation of our strategy and our mission,' said Abrar Mir, Co-Founder and Managing Partner, Quadria Capital. 'It reflects deep global investor conviction in the transformational opportunity in Asian Healthcare, where social impact and financial performance go hand in hand.'
Global Institutional Backing Across Continents
At a time when global capital is cautious, Quadria's ability to consistently attract top-tier global investors underscores the strong conviction in its investment strategy and the undeniable opportunities in the Asian healthcare market.
Quadria Capital's largest existing backers include prominent North American and European sovereign wealth funds, asset managers, and strategic corporates. The Fund also secured new commitments from globally recognized institutional investors. Most notably, there was strong backing from leading institutions across the GCC, including Saudi Arabia, the UAE, and Bahrain. The fundraise further attracted interest from India, with fresh capital from major banks, insurance companies, and family offices. Additionally, the Fund received robust re-up commitments from impact investors – underscoring Quadria's continued dedication to scalable, high-impact healthcare businesses that deliver lifesaving care to underserved populations across Asia.
Positioned for Structural Growth in Asia's $5 Trillion Healthcare Market
'With Asia expected to drive 40% of global healthcare growth by 20301, Fund III positions Quadria to lead a new era of private capital-driven healthcare transformation across the region,' Abrar Mir added.
'Asia's healthcare sector is at a pivotal moment, and it will remain in the limelight in 2025, especially with investment interest in India in areas like single-specialty hospitals, diagnostic chains, medical devices, and pharmaceutical manufacturing, which includes APIs and CDMOs. This sector will see growth because of higher healthcare consumption, cost-efficiency initiatives, and deepening technology integration. We are entering a golden decade of healthcare transformation. Our investment philosophy centers on forging deep partnerships with India's healthcare visionaries as the 'partner of choice', providing strategic guidance and operational support to help them scale their businesses and achieve market leadership,' said Dr Amit Varma, Co-Founder and Managing Partner, Quadria Capital.
India As A Core Market for Healthcare Innovation and Investment
Quadria Capital's investment thesis is especially relevant in India, where healthcare transformation is both a national imperative and a private capital opportunity. India is emerging as a strategic manufacturing hub as global pharmaceutical and MedTech supply chains shift towards the country
Per capita healthcare spend in India stands at just $74, significantly below regional peers like Thailand ($364) and Malaysia ($487), with nearly 50% of all healthcare costs paid out-of-pocket
The new fundraise can fuel Indian healthcare innovation by strategically deploying capital in high-growth sectors like specialised care and pharma manufacturing, with a focus on building scalable, affordable solutions for over a billion people.
Fund III will build a diversified portfolio of approximately 10 market-leading companies, taking both significant minority and majority stakes, and further scaling impact through targeted co-investments from Limited Partners (LPs).
Already nearly 40% deployed – including closed and signed investments – the fund has invested in Aragen Life Sciences (a global CRDMO serving over 400 pharma clients), NephroPlus (Asia's largest dialysis chain), and Maxivision (India's leading eye care chain). Two new investments in Southeast Asia are expected soon. Fund III builds on Quadria Capital's track record of successful exits from Funds I and II, underscoring the strength of its investment strategy, operational expertise and ability to distribute capital back to investors.
About Quadria:
Founded in 2012, Quadria Capital is Asia's premier healthcare investor managing over US$4 billion in assets across 27 investments in South and Southeast Asia including India, Vietnam, Indonesia, Malaysia and Singapore. Quadria Capital aims to create significant and sustainable shareholder value by partnering with exceptional healthcare businesses to enhance their impact and scale, while generating superior returns for investors.
For more information, please visit www.quadriacapital.com
1https://www.bcg.com/publications/2025/india-the-unmissable-asia-healthcare-opportunity
View source version on businesswire.com: https://www.businesswire.com/news/home/20250526913375/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a few seconds ago
- Business Wire
TME Pharma Provides Update About Additional Strategy
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, is pleased to share an update regarding its strategic repositioning. Pursuing stable, cash-generating business opportunities to achieve positive operational cash flow at the holding company level Leveraging tax loss carry forwards Repositioning to enhance shareholder value creation, while maintaining the ultimate strategic focus on the development of NOX-A12 and NOX-E36 assets Gained access to the crypto-markets via newly established crypto brokerage account TME Pharma NV is currently a holding company. Management will now implement and strengthen this structure through complementary, revenue-generating initiatives to cover operating costs. Parallel to its core biotechnology activities, the company is exploring potential acquisitions and partnerships in stable, profitable businesses. These efforts are aimed at creating a fundamentally profitable corporate structure in which revenues from non-core activities will support and strengthen the further development of its patented drug candidates, which remain the company's flagship products, NOX-A12 and NOX-E36. The company holds over €150 million in tax loss carryforwards, which may provide financial benefit if profitable operations are established. A specialist firm is actively assessing opportunities for TME Pharma NV to use these tax assets. Over the past two decades, TME Pharma has made significant investments in its development programs, resulting in promising scientific and clinical results. Shareholders have not yet been able to benefit from this strong fundamental performance, partly due to high dilution. Management's ambition is to break with this trend and has already taken measures to limit further dilution. As previously announced, the company successfully closed non-dilutive financing of €2.05 million in May, thanks in part to the support of the CEO, who subscribed to €600,000 of these bonds. As a next step, management believes that a diversified, profit-driven structure will provide a stronger foundation for unlocking the full potential of its key assets, NOX-A12 and NOX-E36, which ultimately represents true shareholder value. As of June 30, a crypto-related investment was permitted under the current treasury policy. On July 24th, TME Pharma successfully registered with a leading European crypto broker. The company is actively evaluating opportunities in other crypto- and crypto related investments, with a disciplined approach to balancing risk and return. Diede van den Ouden, Chief Executive Officer, stated: 'Our core objective remains consistent: we firmly believe that our key assets, NOX-A12 and NOX-E36, hold substantial value. The strategic framework we have now put in place is designed to create the optimal conditions for unlocking and enhancing shareholder value. TME Pharma is positioning itself to become a financially robust group, capable of making targeted, flexible investments in high-potential projects.' TME Pharma will seek shareholder approval as required for any potential transactions which emerge as part of the new strategy and issue press releases on all material developments. About TME Pharma TME Pharma is a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases. The company's lead compounds have been designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. The company's two lead assets are: NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer), which is being studied (GLORIA Phase 1/2 clinical trial) in newly-diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. The US FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma, and TME Pharma was awarded Fast Track Designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe. NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), which is being evaluated in ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effect. The company, under the leadership of its new CEO, Diede van den Ouden, who joined in the June 2025, is currently undertaking a strategic restructuring with the goal of providing the financial resources to unlock the value of NOX-A12 and NOX-E36. These steps include: Raising funds from alternative sources (€1,7 million raised in May 2025, including €500,000 from the new CEO) Pursuing stable, cash-generating business opportunities to achieve positive operational cash flow at the holding company level Leveraging tax loss carry forwards Gaining exposure to digital assets via newly established crypto brokerage account Further information can be found at: About the GLORIA Study GLORIA (NCT04121455) is TME Pharma's dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 in the expansion arm in which NOX-A12 is combined with radiotherapy and bevacizumab. About the OPTIMUS Study OPTIMUS (NCT04901741) is TME Pharma's planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients. Disclaimer Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements.' Forward-looking statements are based on TME Pharma's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma's ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law.
The Hill
a few seconds ago
- The Hill
Inflation, Gaza, Epstein: Fires await Trump back in US
It's Tuesday. August is so close I can feel it — both figuratively and literally with this brutal heat. 🥵 In today's issue: Trump puts bow on Scotland trip Challenges facing president in DC Mayor says NYC gunman targeted NFL America's first coast-to-coast rail deal I hope Trump packed his fire extinguisher: President Trump opened a new golf course in Scotland this morning and is now returning to the U.S. to 'put out fires all over the world,' as he put it. What are those fires, you may ask? 🔥 First, there's the economy: The next four days may determine the strength of the U.S. economy. Trump's ongoing trade war has magnified these metrics — and any weaknesses in the economy will put the president on defense. Wednesday — the Fed: The Federal Reserve will determine Wednesday whether to lower interest rates. It's expected to keep the rates steady, much to Trump's chagrin. Thursday — price data: Economists are bracing for Thursday's inflation data from the Commerce Department. They're expecting price increases from Trump's tariffs. Friday — trade deadline: Trump's 'reciprocal' tariffs on dozens of countries are set to take effect Friday. White House trade talks are intensifying in the meantime. Friday — the jobs report: July's jobs report will be published Friday at 8:30 a.m. EDT. Economists are expected to see a rise in unemployment and a slowing pace of job creation. Read more on why these four economic metrics matter so much. 🔥 Next, there's the hunger crisis in Gaza: On Monday, Trump acknowledged the dire starvation happening in Gaza, signaling a break with Israeli Prime Minister Benjamin Netanyahu. Trump told reporters he did 'not particularly' agree with Netanyahu's claim that there is no starvation happening in Gaza. Trump has not gone as far as some European leaders in recognizing a Palestinian state. But his support for Netanyahu appears to be slowly eroding. Just in: The U.K. just announced it would plan to recognize Palestinian statehood by September if Israel doesn't take 'substantive steps' to end the humanitarian crisis in Gaza, The New York Times reports. 🔥 Next, the Epstein situation is snowballing: Jeffrey Epstein 's accomplice, Ghislaine Maxwell, appealed her conviction to the Supreme Court. Meanwhile, Senate Judiciary Committee ranking member Dick Durbin (D-Ill.) is demanding the Justice Department turn over everything from its interviews with Maxwell. Trump has fiercely pushed back on reports that he had a closer relationship with Epstein than previously known, but he can't escape it. But the drip, drip, drip of reporting is making it harder for Trump to dismiss. 🔥 Then, there's Trump's deportation effort: The Justice Department (DOJ) filed a formal complaint Monday, alleging misconduct by U.S. District Judge James Boasberg over Trump's high-profile deportations. Remember how Boasberg challenged the legality of Trump's deportation flights to a notorious megaprison in El Salvador in March? Well, the DOJ is demanding he be removed from the case. Trump has been battling with Boasberg since March, but the letter was a major escalation. For more legal coverage, sign-up for The Gavel, The Hill's courts newsletter written by Ella Lee and Zach Schonfeld. Click here to sign up & get it in your inbox. 🔥 And finally, there's Russia: Trump shortened Russia's deadline to agree to a ceasefire with Ukraine to 'about 10 or 12 days' Monday. Russian President Vladimir Putin appeared to scoff at this threat, as Russian strikes killed at least 22 people in Ukraine overnight. 🗨️ Follow today's live blog ➤ SO, HOW WAS THE SCOTLAND TRIP?: It was a mix of work and play. 🤝 On the work side: Trump came out of this trip with a trade deal with the European Union (EU)! 'There was still some vagueness around specifics, but the basic gist of the deal is that European imports to the U.S. will mostly be tariffed at 15 percent,' reports The Hill's Niall Stanage. ⛳ On the play side: Trump opened a new golf course in memory of his late mother. The golf course is in Aberdeen, which is on the east coast of Scotland. ➤ MORE READS: The New York Times: Trump Is Winning His Trade War. What Will That Mean for the Economy? The Atlantic: The Corrupt Bargain Behind Gaza's Catastrophe NBC News: 'Worst-case scenario of famine' unfolding in Gaza under Israel's offensive, global authority on hunger says The Washington Post: We texted nearly 1,100 Americans about Trump and the Epstein files. Here's what they said. The deadliest NYC mass shooting in 25 years: A gunman opened fire in a Midtown Manhattan skyscraper Monday, killing four people and injuring a fifth. The suspect has been identified as 27-year-old Shane Tamura. Tamura allegedly entered the building that housed Blackstone and the National Football League (NFL). He opened fire before dying by suicide. What do we know about his motive?: The New York Times noted the gunman had driven from Nevada. New York City Mayor Eric Adams (D) said the gunman was trying to target the NFL headquarters but took the wrong elevator. Adams says a note was found with the gunman, which blamed the NFL for his brain injury. 'He was not an NFL player,' Adams said. 'It appears as though he was blaming the NFL for his CTE [Chronic traumatic encephalopathy]… and he shot himself and took his own life. Shot himself in the chest. It appears to have been that he wanted to preserve his brain for reason of research.' Among the victims: An off-duty NYPD officer was killed. Didarul Islam was a 36-year-old immigrant from Bangladesh who had served as a New York City police officer for more than three years. CNN pointed out this is the deadliest gun attack in New York City in 25 years. What a wild stat. It's also the highest-profile shooting in NYC since the UnitedHealthcare CEO was killed in December. ➤ SIGHTS AND SOUNDS IN NYC: 📸 Blackstone employees barricaded the door — this is both incredibly chilling and impressive. Who wants to tell Mr. George Russell?: Two railroad companies reached an $85 billion deal this morning, creating the U.S.'s first-ever coast-to-coast rail operator. Specifically: Union Pacific wants to buy Norfolk Southern. Why this matters to you: It could speed up deliveries across America. 'The railroads said the tie-up would streamline deliveries of raw materials and goods across the country by eliminating several days of delays when shipments are handed off between railroads.' (AP) But there's a big caveat: The deal still needs to be approved by antitrust regulators. The Associated Press (AP) noted there's a 'very high bar for railroad deals after previous consolidation in the industry led to massive backups and snarled traffic.' COMING UP The House is out. The Senate is in. President Trump is flying back to Washington from Scotland. (All times EST) 2 p.m.: State Department spokesperson Tammy Bruce briefs reporters. 💻 Livestream 2:15 p.m.: Two Senate votes. More votes are expected today. 📆 Today's agenda 7:20 p.m.: Trump arrives at the White House. 🐝 INTERNET BUZZ 🥑 Free guac alert!: Chipotle is giving out free guacamole Thursday for National Avocado Day. The catch: You have to be a rewards member. The code is AVO2025. 🍽️ Alexa, convert this article into a checklist: The New York Times published its new list of ' The Best 25 Best Restaurants in Washington, D.C., Right Now.' It begins with '2Fifty Barbecue,' so I know this list is legit. 👋 AND FINALLY… ^ If you have, I beg you to send me that footage.
Bloomberg
2 minutes ago
- Bloomberg
Harsh Reality of US Trade Deal Stirs EU Angst
European Union leaders are working through the consequences of their new trading arrangement with the US, and confronting the reality of just how far they have fallen. The terms of the framework deal agreed on Sunday will mean a significant hit to European companies — the EU accepted a tripling of tariffs to 15% on most exports to the US and will keep its own levies on American goods to 1% or less once the pact goes into effect.
